Covaxin booster dose safe: Bharat Biotech
Covaxin manufacturer Bharat Biotech on Saturday said that the booster dose trials have shown "promising results" of long-term safety with "no serious adverse events" The Hyderabad-based company announced the results on the safety and immunogenicity of COVAXIN (BBV152), a whole-virion inactivated COVID-19 vaccine as a booster dose."Covaxin trial demonstrated long-term safety with no...
Covaxin manufacturer Bharat Biotech on Saturday said that the booster dose trials have shown "promising results" of long-term safety with "no serious adverse events" The Hyderabad-based company announced the results on the safety and immunogenicity of COVAXIN (BBV152), a whole-virion inactivated COVID-19 vaccine as a booster dose.
"Covaxin trial demonstrated long-term safety with no serious adverse events. 90 per cent of recipients had a detectable neutralizing antibody response against the wild-type strain (six months after the second dose)." Bharat Biotech said in an official statement.
For more details, check out the full story on the link below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd